Article Text

Download PDFPDF
Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In pregnant women at risk, is prophylactic use of antiplatelet agents (such as aspirin and dipyridamole) effective for preventing or delaying the development of pre-eclampsia as well as other related maternal and child outcomes?

Clinical impact ratings FP/GP/Obstetrics ★★★★★★☆ Obstetrics ★★★★★★☆


Embedded ImageData sources:

the Cochrane Pregnancy and Childbirth Group trials register (September 2003), the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 2, 2003), EMBASE/Excerpta Medica (1994–2003), and congress proceedings of the International and European Societies for the Study of Hypertension in Pregnancy (up to 2002).

Embedded ImageStudy selection and assessment:

randomised controlled trials (RCTs) that compared any antiplatelet agent (such as low dose aspirin or dipyridamole) with a control condition comprising placebo or no antiplatelet agent in pregnant women considered to be at risk of developing pre-eclampsia. Exclusion criteria included comparisons of 1 antiplatelet agent with another, and of antiplatelets with other interventions. Study quality was assessed …

View Full Text


  • For correspondence: Dr L Duley, Institute of Health Sciences, Oxford, UK.

  • Sources of funding: not stated.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd